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Abstract
Background: Metachromatic leukodystrophy (MLD) is a severe neurometabolic disease caused mainly by deficiency of
arylsulfatase A encoded by the ARSA gene. Based on epidemiological surveys the incidence of MLD per 100 000 live births
varied from 0.6 to 2.5. Our purpose was to estimate the birth prevalence of MLD in Poland by determining population
frequency of the common pathogenic ARSA gene mutations and to compare this estimate with epidemiological data.
Methodology: We studied two independently ascertained cohorts from the Polish background population (N,3000 each)
and determined carrier rates of common ARSA gene mutations: c.459+1G.A, p.P426L, p.I179S (cohort 1) and c.459+1G.A,
p.I179S (cohort 2).
Principal Findings: Taking into account ARSA gene mutation distribution among 60 Polish patients, the expected MLD birth
prevalence in the general population (assuming no selection against homozygous fetuses) was estimated as 4.0/100 000
and 4.1/100 000, respectively for the 1
st and the 2
nd cohort with a pooled estimate of 4.1/100 000 (CI: 1.8–9.4) which was
higher than the estimate of 0.38 per 100 000 live births based on diagnosed cases. The p.I179S mutation was relatively more
prevalent among controls than patients (OR=3.6, P=0.0082, for a comparison of p.I179S frequency relative to c.459+1G.A
between controls vs. patients).
Conclusions/Significance: The observed discrepancy between the measured incidence of metachromatic leukodystrophy
and the predicted carriage rates suggests that MLD is substantially underdiagnosed in the Polish population. The
underdiagnosis rate may be particularly high among patients with p.I179S mutation whose disease is characterized mainly
by psychotic symptoms.
Citation: Ługowska A, Ponin ´ska J, Krajewski P, Broda G, Płoski R (2011) Population Carrier Rates of Pathogenic ARSA Gene Mutations: Is Metachromatic
Leukodystrophy Underdiagnosed? PLoS ONE 6(6): e20218. doi:10.1371/journal.pone.0020218
Editor: Bob Lightowlers, Newcastle University, United Kingdom
Received September 22, 2010; Accepted April 27, 2011; Published June 10, 2011
Copyright:  2011 Ługowska et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Institute of Psychiatry and Neurology (Warsaw, Poland; www.ipin.edu.pl); grant no. 40/2009 and Medical University in
Warsaw (www.wum.edu.pl) grant no. 1WY/WB1/10. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: alugipin@yahoo.com (AŁ); rploski@wp.pl (RP)
Introduction
Metachromatic leukodystrophy (MLD; OMIM 250100) is a
severe demyelinating disease inherited in an autosomal recessive
fashion. MLD is caused by deficient activity of lysosomal hydrolase
arylsulfatase A (ARSA; EC 3.1.6.8) which leads to sulfatide
storage. Apart from an MLD type caused by saposin B deficiency
all clinical forms of MLD are due to mutations in the ARSA gene
located on chromosome 22q13. The overall incidence of MLD
varies from 1 in 40 000 to 1 in 170 000 in different populations [1]
most likely reflecting different pathogenic mutation carriage rates
as well as differences in the diagnosis rate. Based on this data it can
be assumed that carrier frequency for MLD varies from ,1:100 to
1:130 implying that among ,3500 individuals from the general
population 17–35 persons should be MLD carriers. Three MLD
causing mutations in the ARSA gene – c.459+1G.A, p.P426L,
and p.I179S are responsible together for approximately 50% of
mutated alleles in MLD patients from Poland [2].
The aim of this study was to estimate the birth incidence of
MLD in Poland by determining the population frequency of the
common MLD causing mutations and compare this estimate with
epidemiological data.
Results
Screening population cohort 1
During the initial screening performed among subjects under-
going paternity testing results were obtained for 3 320, 3 467, and
3 159 samples, respectively for mutations c.459+1G.A, p.P426L,
and p.I179S. Five heterozygous carriers for c.459+1G.A, seven
heterozygous carriers for p.P426L, and 11 heterozygous carriers
for p.I179S were identified (Table 1) yielding a joint population
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that among Polish MLD patients these three mutations were
present in 66 out of 120 chromosomes (55%), the population
frequency of all other pathogenic ARSA gene mutations could be
estimated as 0.28% (CI: 0.18–0.45) and joint population frequency
of all pathogenic mutations in ARSA gene as 0.63% (CI: 0.41–0.98,
Table 1). Based on these values the mutation carriage rate per 10
000 was calculated as 125 (CI: 81–194, Table 1) whereas the
expected prevalence of fetuses with two pathogenic ARSA gene
mutations was estimated as 4.0 per 100 000 conceived fetuses (or 1
in 25 000) with CI from 1.7 to 9.6.
We noted a trend for difference in the relative distribution of the
tested ARSA gene mutations between MLD patients and controls.
Among the patients the c.459+1G.A mutation was the most
prevalent accounting for 42.4% or 28/66 of the three tested
variants whereas p.I179S had lower frequency (28.8% or 19/66 of
the tested variants). Among controls this correlation was reversed:
c.459+1G.A was the least prevalent (21.7% or 5/23) whereas
p.I179S had the highest frequency (47.8% or 11/23). When
frequency of the p.I179S mutation was expressed relative to
frequency of the c.459+1G.A mutation a trend with borderline
statistical significance of P=0.051 [Odds Ratio (OR)=3.24, CI:
0.99–10.51] was observed in a comparison between controls (11/
5) vs. patients (19/28, Table 2). The relative frequency of the
p.P426L mutation was similar among patients (28.9% or 19/66)
and controls (30.4% or 7/23, Table 2).
Screening population cohort 2
In order to verify these findings and further explore the trend
for the increased frequency of p.I179S relative to c.459+1G.A
among controls vs. patients we analyzed prevalence of these two
mutations in an independently ascertained population cohort from
the WOBASZ study (population cohort 2). Results were obtained
for 3 019 and 2 937 samples for c.459+1G.A and p.I179S,
respectively. Four heterozygous carriers of c.459+1G.A and 11
heterozygous carriers of p.I179S were identified yielding the
respective estimates of gene frequency of 0.07% (CI: 0.03–0.17)
and 0.19% (CI: 0.1–0.34, Table 1). Since these two mutations
Table 1. Screening for the most common ARSA gene mutations in a Polish population.
c.459+1G.A p.P426L p.I179S
All mutations
including unknown
Population cohort 1
Individuals tested 3 320 3 467 3 159 3 315*
Observed heterozygotes 5 7 11 -
Gene frequency % (CI) 0.08 (0.03–0.18) 0.1 (0.05–0.21) 0.17 (0.1–0.31) 0.63 (0.41–0.98)
Carrier frequency per 10 000 (CI) 15 (6–35) 20 (10–42) 35 (19–62) 125 (81–194)
Affected per 100 000: 4.0 (CI: 1.7–9.6)
Population cohort 2
Individuals tested 3 019 - 2 937 2 978*
Observed heterozygotes 4 - 11 -
Gene frequency % (CI) 0.07 (0.03–0.17) - 0.19 (0.1–0.34) 0.64 (0.37–1.11)
Carrier frequency per 10 000 (CI) 13 (5–34) - 37 (21–67) 128 (74–220)
Affected per 100 000: 4.1 (CI: 1.4–12.4)
Population cohort 1+2
Individuals tested 6 339 - 6 096 6 218*
Observed heterozygotes 9 - 22 -
Gene frequency % (CI) 0.07 (0.04–0.13) - 0.18 (0.12–0.27) 0.64 (0.42–0.97)
Carrier frequency per 10 000 (CI) 14 (7–27) - 36 (24–55) 126 (84–192)
Affected per 100 000: 4.1 (CI: 1.8–9.4)
*mean number of subjects tested for each mutation.
doi:10.1371/journal.pone.0020218.t001
Table 2. Distribution of the tested mutations among controls and MLD patients.
Group/ mutation
c.459+1G.A
n
p.P426L
n (OR [CI]); P
p.I179S
n (OR [CI]); P
Population 1; nmean=3 315 5 7 (2.06 [0.59–7.20]); 0.27 11 (3.24 [0.99–10.51]); 0.051
Population 2; nmean=2 978 4 - 11 (4.05 [1.16–14.0]); 0.026
Population 1+2; nmean=6 218 9 - 22 (3.60 [1.37–9.43]); 0.0082
Patients, Poland; n=60 28
1 19
2 19
3
19 females, 12 males;
2 5 females, 8 males;
3 9 females, 10 males.
OR (Odds Ratio) and P value calculated for the frequency of p.P426L or p.I179S among controls vs. patients. For each mutation its frequency was expressed relative to
the frequency of c.459+1G.A. For example, in case of p.I179S in Population 1+2: OR=(22/9) / (19/28)=3.60.
doi:10.1371/journal.pone.0020218.t002
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patients the population frequency of all pathogenic ARSA gene
mutations could be estimated as 0.64% (CI: 0.37–1.11, Table 1)
and their carriage rate as 128 per 10 000 (CI: 74–220, Table 1).
Thus, the expected prevalence of fetuses conceived with two MLD
causing mutations is 4.1 per 100 000 conceived fetuses (or 1 in 24
390) CI from 1.4 to 12.4.
Analysis of frequency of the p.I179S mutation relative to
c.459+1G.A showed a statistically significant difference (OR=4.05,
CI: 1.16–14.0, P=0.026) between population cohort 2 (11/4) and
patients (19/28, Table 2).
Analysis of pooled population cohorts
Since there were no statistically significant differences between
mutation frequency estimates based on the two population cohorts
(P.0.8 in both comparisons) we also analyzed the data after
pooling. This analysis was based on 6 339 subjects tested for
c.459+1G.A, nine of whom were positive and 6 096 subjects
tested for p.I179S of whom 22 were positive yielding the estimates
of gene frequencies equal to 0.07% (CI: 0.04–0.13) and 0.18% (CI:
0.12–0.27), and carrier frequencies per 10 000 equal to 14 (CI: 7–
27) and 36 (CI: 24–55), respectively for c.459+1G.A and p.I179S
(Table 1).
By taking into account distribution of ARSA gene mutations
among patients the gene frequency of all pathogenic mutations
was estimated as 0.64 with CI from 0.42 to 0.97 and carriage rate
per 10 000 as 126 (CI: 84–192, Table 1). Using the pooled cohort
the expected prevalence of fetuses with two pathogenic ARSA gene
mutations was estimated as 4.1 per 100 000 conceived fetuses (or 1
in 24 390) with CI from 1.8 to 9.4 (Table 1).
Analysis of frequency of the p.I179S mutation relative to
c.459+1G.A showed a statistically significant difference (OR=3.60,
CI: 1.37–9.43, P=0.0082) between pooled population cohorts (22/9)
and patients (19/28, Table 2).
Prevalence of MLD in Poland based on diagnosed cases
Analysis of the graph showing cumulative number of MLD
cases diagnosed per year plotted against year of birth showed that
the curve was linear from year 1975 to 2004 (Figure 1) indicating
that this period was optimal for prevalence calculation [3]. By
dividing total number of MLD patients born in this period by
number of all children born alive in Poland in the respective time
we obtained an estimate of MLD incidence equal to 0.38 per 100
000 (Table S1).
Discussion
In the present study we determined the general population
carriage rates of three pathogenic ARSA gene mutations:
c.459+1G.A, p.P426L, and p.I179S. After taking into account
the frequency of these mutations among MLD patients, the
carriage rate of all pathogenic ARSA gene mutations was estimated
as 125/10 000 or 1/80 whereas disease prevalence among
conceived fetuses was 4.0 per 100 000. These estimates were
closely confirmed by analysis of an independently ascertained
population cohort (the carriage rate of 128/10 000 and disease
prevalence equal to 4.1 per 100 000). An analysis using a pooled
cohort of . 6 000 subjects yielded carriage rate per 10 000 equal
to 126 or 1 in 79 and prevalence of fetuses conceived with two
pathogenic MLD causing mutations of 4.1 per 100 000 (CI: 1.8–
9.4). We also observed that the p.I179S mutation was relatively
more frequent among controls than patients. In particular when
p.I179S frequency was expressed relative to c.459+1G.Aa
statistically significant difference was observed between controls vs.
patients (OR=3.6, P=0.0082).
The expected prevalence of fetuses conceived with two
pathogenic ARSA mutations in Poland (4.1 per 100 000) is
substantially higher than the birth prevalence of MLD based on
diagnosed cases (0.38 per 100 000 live births as determined by us
or 0.53 per 100 000 (1 in 189 000) as previously reported in Poland
[4]). Our estimate is also higher than similar estimates made in
other Caucasian populations: 1 in 40 000 (i.e. 2.5/100 000) in
Northern Sweden [5], 1 in 130 000 (i.e. 0.77/100 000) in France
[6], 1 in 170 000 (i.e. 0.59/100 000) in Germany [7], 1.85/100
000 in Portugal [8], 1.42/100 000 in the Netherlands [9], 1.43/
100 000 in Turkey [10], and 1/40 000 (i.e. 2.5/100 000) in the
Washington State [11]. Notably, except for Northern Sweden [5],
Figure 1. Cumulative number of new MLD cases diagnosed per year plotted against year of birth. The period from years 1975–2004 was
used to calculate MLD incidence. The data used to draw the figure are shown in Table S1.
doi:10.1371/journal.pone.0020218.g001
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prevalence is lower than the lower bound of the CI of our
estimate (i.e. 1.8/100 000), thus indicating that the observed
differences are statistically significant.
The birth prevalences of MLD were higher only in small,
geographically or ethnically isolated communities like in Habba-
nite Jews in Israel (1 in 75) [12], Arab inhabitants of Israel (1 in
8000) [13], Navajo Indians (1 in 6400) [14], and Eskimos (1 in
2500) [15].
This discrepancy between our estimate and observed incidence
of MLD in Poland may have several causes. It should be
emphasized that all birth prevalence values reported so far were
based on direct diagnoses whereas our estimations are the first
based on the mutation carrier rates in general population. It is
possible that mutations in the ARSA gene resulting in the severe
phenotype can lead to prenatal or perinatal loss of affected fetuses
thus decreasing prevalence among live born children. Whereas in
Poland prenatal screening for MLD has not been performed,
prenatal diagnosis in families with MLD probands is available
which is likely to decrease number of affected individuals born. We
also cannot fully exclude that some patients are diagnosed abroad
and thus not referred to the Institute of Psychiatry and Neurology
in Warsaw. However, this should not be frequent since in the
Polish health system referral to foreign centers occurs only in
exceptional cases.
Our findings may also be influenced by a distinct phenotype
associated with the p.I179S and possibly other yet unknown
mutations. Since patients with the p.I179S mutation suffer initially
mainly from psychotic manifestations it is possible, that some
individuals from this group are misdiagnosed as affected with
atypical schizophrenia [16,17]. The diagnostic issues may be
particularly pronounced in case of p.I179S homozygotes since no
such MLD patients have been described so far. In this context it is
particularly noteworthy that we observed statistically significant
inverse relationship between relative frequencies of p.I179S and
c.459+1G.A mutations among patients vs. controls, consistent
with possibility of underdiagnosis of cases with the former
mutation. The problem of misdiagnosed patients is also actual
for the adult onset patients in whom the beginning stages of the
disease may be mild and difficult to detect.
The close similarity of carriage rates of c.459+1G.A and
p.I179S in a population coming mainly from Central Poland (the
paternity testing sample, cohort 1) and population representative
of the whole country (the WOBASZ sample, cohort 2) supports
ethnic homogeneity of Polish population and strengthens our
conclusions which rely also on data from patients coming from the
whole Polish territory. Homogeneity of contemporary Polish
population is consistent with studies on distribution of Y
chromosome markers which are particularly sensitive to popula-
tion substructure [18,19].
A limitation of our study is caused by lack of appropriate
molecular testing allowing to rigorously exclude related individuals
from the population cohorts studied. Further, whereas our
determination of background population carriage rates is appar-
ently robust the data on mutation distribution among patients may
not be so reliable as they come from a single group of limited size.
Although our statistical approach takes this into account it would
be interesting to verify our conclusions in another population and
MLD patients groups.
In conclusion, MLD and other lysosomal disorders are
considered to be orphan diseases but the expected incidence of
fetuses conceived with two pathogenic ARSA mutations of 4.1 in
100 000 and heterozygote frequency of 1 in 79 negate this
statement. One possible reason for the discrepancy between
observed and expected prevalence of MLD may be related to
disease underdiagnosis, especially among patients with p.I179S
mutation.
Materials and Methods
Population samples
Population cohort 1. Three thousand five hundred DNA
samples were obtained from anonymous DNA samples collection
of Department of Forensic Medicine WUM which has been
described previously [20,21]. These samples come from couples
who underwent genetic testing because of disputed paternity
(alleged fathers and mothers of tested children, no duplicates or
obviously related individuals, all Caucasians living mainly in
Central Poland, male:female ratio ,1, mean age 30.7 years,
standard deviation 10.0, range from 15 to 77 years). Informed
consents were not obtained for this cohort, because the samples
and the obtained data were analyzed anonymously. This protocol
has been approved by and obtained a positive opinion from the
Bioethics Committee at the Institute of Psychiatry and Neurology
in Warsaw, which specifically approved the waiver of consent.
Population cohort 2. This cohort consisted of three
thousand one hundred subjects randomly selected from the
participants of WOBASZ study [22,23]. The WOBASZ study
was a cross-sectional epidemiological study based on subjects
randomly selected from Polish population register of permanent
residents aged 20–74 years. The sampling scheme was stratified by
sex, administration units and type of urbanization. Data were
collected from January 2003 to December 2005. The response rate
was 70%. The study was approved by The Medical Ethics
Committee of National Institute of Cardiology in Warsaw and
each participant gave a written consent for taking blood sample for
DNA isolation and genetic analyses [22,23].
Patients
The distribution of the c.459+1G.A, p.P426L and p.I179S
mutations in the ARSA gene among MLD patients was determined
based on 60 unrelated probands who were all typed for these
variants for diagnostic purposes as described previously [24]. This
group included 43 individuals described earlier [24] as well as 17
additional patients (Polish Caucasians, male: female ratio ,1, age
1.5–51 yr) . Since the Department of Genetics at the Institute of
Psychiatry and Neurology is the only one centre diagnosing MLD
in Poland these patients can be regarded as being randomly
selected across the national population.
Typing
In population cohort 1 the screening for the c.459+1G.A,
p.P426L, and p.I179S mutations was performed by PCR-RFLP
methods [2]. In population cohort 2 we used a TaqMan method
based on Assay on Demand from Life Technologies and real time PCR
apparatus ABI Prism 7500. In all TaqMan experiments at least
three positive samples verified by PCR-RFLP were used as
controls. For all mutations positive results were verified by re-
analysis of samples from the original stock.
Statistical analysis
Joint population frequency of tested mutations (ftested_pop.) was
estimated by summing individual frequencies. The population
frequency of mutations which were not tested including those
which are unknown (fn.tested_pop.) was estimated from the prevalence
of the tested mutations among MLD patients from our center
(ftested_pat.). Assuming similar penetrance for all MLD mutations
their relative frequencies among patients and population controls
Is Metachromatic Leukodystrophy Underdiagnosed?
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ftested_pat.. Similarly, population frequency of all pathogenic
mutations fall_pop = ftested_pop / ftested_pat. Based on data available
from patients ftested_pat. was estimated as 66/120 or 55% for
Population cohort 1 and 47/120 or 39.2% for Population cohort 2
as well as the pooled cohorts. The expected population frequencies
of (i) carriers of pathogenic mutations and (ii) of affected
individuals (i.e. those with two pathogenic ARSA gene mutations)
were estimated from Hardy-Weinberg law as (i) 26 fall_pop 6 (1-
fall_pop) and (ii) fall_pop
2.
Ninety five percent confidence intervals (CI) for mutation
frequencies were calculated according to Wilson [25] whereas CI
for the ratio ftested_pop / ftested_pat. was calculated according to Miettinen
and Nurminen as ratio of proportions allowing to take into account
the uncertainty associated with estimates of both ftested_pop and ftested_pat.
[26]. During analysis of population cohort 1 for calculation of CI for
ftested_pop it was assumed that 3 315 samples were tested which
represents a mean of numbers actually tested for each mutation (i.e. 3
320, 3 467, and 3 159). Analogous approach was used for Population
cohort 2 and pooled cohort. Computations of CI were done using
spreadsheet downloaded from (accessed 20.01.2007):http://www.
cardiff.ac.uk/medicine/epidemiology_statistics/research/statistics/
ODDSRATIOANDRR.xls. Frequency of the p.I179S mutation
expressed relative to frequency of the c.459+1G.A in the general
population and among patients was compared by a chi square test
with one degree of freedom using Statistica software package.
Incidence of MLD in Poland based on diagnosed cases
Incidence (birth prevalence) of MLD in Poland was determined
by the method proposed by Claussen et al. [3]. This method is
based on sorting all ascertained cases according to birth year and
plotting the cumulative number of cases diagnosed per year
against the year of birth. The linear region of the obtained curve
indicates the period free from ascertainment errors due to
inefficient registration (typically in the past) or yet undiagnosed
cases in young subjects (most recent period). In order to estimate
disease incidence, for the time period thus identified the total
number of cases is divided by total number of births [3].
In Poland lysosomal disorders including MLD are diagnosed
exclusively in the Department of Genetics at the Institute of
Psychiatry and Neurology in Warsaw and it was assumed that all
Polish patients with the suspicion of MLD were referred to our
laboratory. The numbers of births per year were obtained from
Polish Central Statistical Office (www.stat.gov.pl/gus).
Supporting Information
Table S1 Demographic data vs. numbers of MLD patients born
in Poland.
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